Подписывайтесь на нас

Одна из главных задач Life4me+ — предотвращение новых случаев заражения ВИЧ-инфекцией и другими ИППП, гепатитом C и туберкулезом.

Приложение позволяет установить анонимную связь между врачами и ВИЧ-позитивными людьми, дает возможность организовать своевременный прием ваших медикаментов, получать замаскированные напоминания о них.

Назад
28 ноября 2013, 00:00
131

Клинические исследования: новая схема лечения ВИЧ

Клинические исследования: новая схема лечения ВИЧ - изображение 1

The trial is being conducted by the CHERUB collaboration - an alliance of HIV researchers at Oxford University, Imperial College London, the University of Cambridge, University College London and King’s College London. It is being funded by a £1.7 million grant from the Medical Research Council (MRC), as part of the Biomedical Catalyst funding stream.

Key preliminary studies by the CHERUB researchers that laid the groundwork for the trial were supported by National Institute for Health Research Biomedical Research Centres (NIHR BRCs) based at the five universities and their NHS trust partners.

Thirty-four million people are infected by HIV worldwide. Antiretroviral therapy (ART) is highly effective at stopping the virus from reproducing, but it doesn’t eradicate the disease, so it has to be taken for life.

HIV carries its genetic code in RNA, a molecule related to DNA, but as part of its lifecycle it copies the code into DNA and merges it with the DNA of human cells it has infected. In some cells this DNA remains dormant (latent) enabling it to stay hidden from the immune system and resist therapy.

Drugs called HDAC inhibitors, which are used as cancer treatments, have been shown to reactivate dormant HIV in the laboratory.

One group of patients in the trial will be given a short course of HDAC inhibitors and an HIV vaccine alongside ART. Another group will get ART with placebos. As part of the study the research team are developing an improved method for detecting latency, which has been one of the difficulties in measuring the success of therapeutic approaches such as this.

The researchers, led by Dr Sarah Fidler at Imperial and Dr John Frater at Oxford, hope the trial will provide proof that a cure is feasible.

“We can only truly know if someone is cured of HIV if we stop giving them antiretroviral therapy,” said Dr Frater of Oxford University. “We’re not going to do that, but we will test if we can reduce the number of HIV-infected cells in these patients. If we can, it will prove in principle that this strategy could work as a cure, even though it will need many more years of further development.”

“We know that targeting the HIV reservoir is extremely difficult,” said Dr Fidler, “but our research in the labs has led to some very promising results. We now have the opportunity to translate that into a possible new treatment, which we hope will be of real benefit to patients.”

Professor Dame Sally C. Davies, Chief Medical Officer and Chief Scientific Adviser at the Department of Health, said: “Research has changed HIV into a long term condition. I am pleased that the world-leading collaborative research within the National Institute for Health Research Biomedical Research Centres has provided the foundations for this major new trial.”

Автор: Лилия Тен

Поделиться в соцсетях